MPI-CDG

The Worldwide Milk Protein Isolate Industry is Expected to Reach $3.45 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022
Food, Beverage, Retail, Human body, Infant, Organic acid, Food, Athlete, Parent, Population, Milk, Growth, Drink, MPI, MPI-CDG, IDFA, CAGR, Agriculture

Milk Protein Isolate is a protein product with a high protein content.

Key Points: 
  • Milk Protein Isolate is a protein product with a high protein content.
  • The booming sports nutrition industry is a key driver of the Milk Protein Isolate market.
  • As per the International Dairy Foods Association (IDFA), the global milk protein isolate market is expected to witness a CAGR of around 6% from 2019 to 2025.
  • For the purpose of this report, the author have segmented into the global Milk Protein Isolate market on the basis of filtration method, application, distribution channel, and region:

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 2, 2022
Lists of diseases, AstraZeneca, Therapy, Leadership, LAD, SLC35C1, Ernst & Young, Patient, Pharmacokinetics, Multiple myeloma, Research, Industry, Ulcerative colitis, Pivotal, Biomarker, AOSD, Asthma, Microcystic lymphatic malformation, CD, Colonoscopy, Safety, Director, Inflammatory bowel disease, Mitchell, Merck, FDA, Program, MPI-CDG, Board, Company, UC, Inflammation, Trial of the century, IND, Review, Johnson & Johnson, Nasdaq, GLOBE, Management, Pharmaceutical industry, NEA

Topline data anticipated in the fourth quarter of 2022

Key Points: 
  • Topline data anticipated in the fourth quarter of 2022
    Cash and cash equivalents of $54.6 million as of December 31, 2021
    WAYNE, Pa. and ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet need in immunology and rare genetic diseases, today announced business updates and year-end financial results for 2021.
  • 2021 was an important year for Avalo in that the Company produced compelling data for AVTX-002 in both acute and chronic inflammatory diseases.
  • Promoted Dr. Garry Neil to Chief Executive Officer and Chris Sullivan to Chief Financial Officer.
  • Mr. Sullivan brings strong financial leadership to Avalo from his prior senior level finance/accounting positions for various Nasdaq-listed life science companies and Ernst & Young.

Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 9, 2021
Population, Safety, IBD, AOSD, Therapy, Mab, LAD, Cohort, Clinical trial, Ulcerative colitis, MM, COVID-19, Research, Crohn's disease, Microcystic lymphatic malformation, Glycosylation, Company, GLOBE, CDG, MPI-CDG, TNFSF14, Birth, Nasdaq, Patient, FDA, Adult, Pharmaceutical industry, Vaccine, Cryptocurrency

WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases today announced business updates and third quarter 2021 financial results.

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases today announced business updates and third quarter 2021 financial results.
  • Avalo had cash and cash equivalents of $71.5 million as of September 30, 2021.
  • The Company anticipates top-line data from the Phase 1b clinical trial in relapsed or refractory MM patients in the fourth quarter of 2021.
  • Third Quarter 2021 Financial Update:
    As of September 30, 2021, Avalo had $71.5 million in cash and cash equivalents, representing a $52.6 million increase as compared to December 31, 2020.

Cerecor Announces Clinical Updates on CERC-301 and CERC-802

Retrieved on: 
Monday, November 11, 2019
Enzymes, Congenital disorders of glycosylation, MPI-CDG, Genetic genealogy, Medical genetics, Mannose phosphate isomerase, MPI, Mannose, Isomerase

Its potential to be, perhaps, safer and more effective in a much broader patient population than our current therapeutic options provide is promising.

Key Points: 
  • Its potential to be, perhaps, safer and more effective in a much broader patient population than our current therapeutic options provide is promising.
  • Dietary monosaccharide formulations have been shown to alleviate several of the clinical manifestations in CDG patients.
  • Biallelic pathogenic variants of the MPI gene lead to enzymatic deficiencies of mannose-6-phosphate isomerase (MPI enzyme) associated with the clinical syndrome MPI-CDG.
  • Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurological conditions.